A simultaneous or sequential combination of brentuximab vedotin and radiotherapy is feasible and well tolerated in patients ...

In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de ...

Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with 10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study. Safety and ...

Researchers sought to determine whether isatuximab and cemiplimab would be safe and effective for patients with relapsed/refractory extranodal NK/T-cell lymphoma.

Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings from ...

Clinical characteristics and treatment outcomes of hepatosplenic T-cell lymphoma: Mayo Clinic experience. Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

(RTTNews) - Corvus Pharmaceuticals, Inc.(CRVS), a clinical-stage biopharmaceutical company, Thursday reported positive data from its Phase 1/1b study of soquelitinib for the treatment of patients with ...